Animal models and antibody assays for evaluating candidate SARS vaccines : Summary of a technical meeting 25-26 August 2005, London, UK
Identifieur interne : 004481 ( Main/Exploration ); précédent : 004480; suivant : 004482Animal models and antibody assays for evaluating candidate SARS vaccines : Summary of a technical meeting 25-26 August 2005, London, UK
Auteurs : Anjeanette Roberts [États-Unis] ; John Wood [Royaume-Uni] ; Kanta Subbarao [États-Unis] ; Morag Ferguson [Royaume-Uni] ; David Wood [Suisse] ; Thomas Cherian [Suisse]Source :
- Vaccine [ 0264-410X ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (analyse), Anticorps antiviraux (biosynthèse), Antiviraux (usage thérapeutique), Arvicolinae, Cochons d'Inde, Cricetinae, Furets, Modèles animaux de maladie humaine, Primates, Rats, Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (immunologie), Virus du SRAS (immunologie), Viverridae.
- MESH :
- analyse : Anticorps antiviraux.
- biosynthèse : Anticorps antiviraux.
- effets indésirables : Vaccins antiviraux.
- immunologie : Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux.
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
- Animal model, Animals, Antibodies, Viral (analysis), Antibodies, Viral (biosynthesis), Antibody, Antiviral Agents (therapeutic use), Arvicolinae, Cricetinae, Disease Models, Animal, Ferrets, Guinea Pigs, Mice, Primates, Rats, SARS Virus (immunology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Vaccine, Viral Vaccines (adverse effects), Viral Vaccines (immunology), Viverridae.
- MESH :
- chemical , adverse effects : Viral Vaccines.
- chemical , analysis : Antibodies, Viral.
- chemical , biosynthesis : Antibodies, Viral.
- chemical , immunology : Viral Vaccines.
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Arvicolinae, Cricetinae, Disease Models, Animal, Ferrets, Guinea Pigs, Mice, Primates, Rats, Viverridae.
Abstract
Severe acute respiratory syndrome (SARS) emerged in the Guangdong province of China in late 2002 and spread to 29 countries. By the end of the outbreak in July 2003, the CDC and WHO reported 8437 cases with a 9.6% case fatality rate. The disease was caused by a previously unrecognized coronavirus, SARS-CoV. Drawing on experience with animal coronavirus vaccines, several vaccine candidates have been developed and evaluated in pre-clinical trials. Available data suggest that vaccines should be based on the the 180 kDa viral spike protein, S, the only significant neutralization antigen capable of inducing protective immune responses in animals. In the absence of clinical cases of SARS, candidate vaccines should be evaluated for efficacy in animal models, and although it is uncertain whether the United States Food and Drug Administration's "animal rule" would apply to licensure of a SARS vaccine, it is important to develop standardized animal models and immunological assays in preparation for this eventuality. This report summarizes the recommendations from a WHO Technical Meeting on Animal Models and Antibody Assays for Evaluating Candidate SARS Vaccines held on 25-26 August 2005 in South Mimms, UK, provides guidance on the use of animal models, and outlines the steps to develop standard reagents and assays for immunological evaluation of candidate SARS vaccines.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000430
- to stream PascalFrancis, to step Curation: 000559
- to stream PascalFrancis, to step Checkpoint: 000511
- to stream Main, to step Merge: 004712
- to stream Pmc, to step Corpus: 001528
- to stream Pmc, to step Curation: 001528
- to stream Pmc, to step Checkpoint: 001168
- to stream PubMed, to step Corpus: 002114
- to stream PubMed, to step Curation: 002114
- to stream PubMed, to step Checkpoint: 002299
- to stream Ncbi, to step Merge: 001634
- to stream Ncbi, to step Curation: 001634
- to stream Ncbi, to step Checkpoint: 001634
- to stream Main, to step Merge: 004197
- to stream Main, to step Curation: 004481
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Animal models and antibody assays for evaluating candidate SARS vaccines : Summary of a technical meeting 25-26 August 2005, London, UK</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>National Institute of Allergy and Infectious Diseases</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Wood, John" sort="Wood, John" uniqKey="Wood J" first="John" last="Wood">John Wood</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Institute for Biological Standards and Control</s1><s2>Potters Bar, Hertfordshire</s2><s3>GBR</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>National Institute for Biological Standards and Control</wicri:noRegion></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>National Institute of Allergy and Infectious Diseases</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ferguson, Morag" sort="Ferguson, Morag" uniqKey="Ferguson M" first="Morag" last="Ferguson">Morag Ferguson</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Institute for Biological Standards and Control</s1><s2>Potters Bar, Hertfordshire</s2><s3>GBR</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>National Institute for Biological Standards and Control</wicri:noRegion></affiliation></author><author><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia</s1><s2>1211 Geneva</s2><s3>CHE</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Cherian, Thomas" sort="Cherian, Thomas" uniqKey="Cherian T" first="Thomas" last="Cherian">Thomas Cherian</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia</s1><s2>1211 Geneva</s2><s3>CHE</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0009303</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 07-0009303 INIST</idno><idno type="RBID">Pascal:07-0009303</idno><idno type="wicri:Area/PascalFrancis/Corpus">000430</idno><idno type="wicri:Area/PascalFrancis/Curation">000559</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000511</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000511</idno><idno type="wicri:doubleKey">0264-410X:2006:Roberts A:animal:models:and</idno><idno type="wicri:Area/Main/Merge">004712</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130694</idno><idno type="RBID">PMC:7130694</idno><idno type="wicri:Area/Pmc/Corpus">001528</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001528</idno><idno type="wicri:Area/Pmc/Curation">001528</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001528</idno><idno type="wicri:Area/Pmc/Checkpoint">001168</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001168</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16930781</idno><idno type="wicri:Area/PubMed/Corpus">002114</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002114</idno><idno type="wicri:Area/PubMed/Curation">002114</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002114</idno><idno type="wicri:Area/PubMed/Checkpoint">002299</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002299</idno><idno type="wicri:Area/Ncbi/Merge">001634</idno><idno type="wicri:Area/Ncbi/Curation">001634</idno><idno type="wicri:Area/Ncbi/Checkpoint">001634</idno><idno type="wicri:doubleKey">0264-410X:2006:Roberts A:animal:models:and</idno><idno type="wicri:Area/Main/Merge">004197</idno><idno type="wicri:Area/Main/Curation">004481</idno><idno type="wicri:Area/Main/Exploration">004481</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Animal models and antibody assays for evaluating candidate SARS vaccines : Summary of a technical meeting 25-26 August 2005, London, UK</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>National Institute of Allergy and Infectious Diseases</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Wood, John" sort="Wood, John" uniqKey="Wood J" first="John" last="Wood">John Wood</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Institute for Biological Standards and Control</s1><s2>Potters Bar, Hertfordshire</s2><s3>GBR</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>National Institute for Biological Standards and Control</wicri:noRegion></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>National Institute of Allergy and Infectious Diseases</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ferguson, Morag" sort="Ferguson, Morag" uniqKey="Ferguson M" first="Morag" last="Ferguson">Morag Ferguson</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Institute for Biological Standards and Control</s1><s2>Potters Bar, Hertfordshire</s2><s3>GBR</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>National Institute for Biological Standards and Control</wicri:noRegion></affiliation></author><author><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia</s1><s2>1211 Geneva</s2><s3>CHE</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author><author><name sortKey="Cherian, Thomas" sort="Cherian, Thomas" uniqKey="Cherian T" first="Thomas" last="Cherian">Thomas Cherian</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Avenue Appia</s1><s2>1211 Geneva</s2><s3>CHE</s3><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>1211 Geneva</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term><term>Animals</term><term>Antibodies, Viral (analysis)</term><term>Antibodies, Viral (biosynthesis)</term><term>Antibody</term><term>Antiviral Agents (therapeutic use)</term><term>Arvicolinae</term><term>Cricetinae</term><term>Disease Models, Animal</term><term>Ferrets</term><term>Guinea Pigs</term><term>Mice</term><term>Primates</term><term>Rats</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe acute respiratory syndrome</term><term>Severe acute respiratory syndrome virus</term><term>Vaccine</term><term>Viral Vaccines (adverse effects)</term><term>Viral Vaccines (immunology)</term><term>Viverridae</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (analyse)</term><term>Anticorps antiviraux (biosynthèse)</term><term>Antiviraux (usage thérapeutique)</term><term>Arvicolinae</term><term>Cochons d'Inde</term><term>Cricetinae</term><term>Furets</term><term>Modèles animaux de maladie humaine</term><term>Primates</term><term>Rats</term><term>Souris</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Vaccins antiviraux (effets indésirables)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (immunologie)</term><term>Viverridae</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Arvicolinae</term><term>Cricetinae</term><term>Disease Models, Animal</term><term>Ferrets</term><term>Guinea Pigs</term><term>Mice</term><term>Primates</term><term>Rats</term><term>Viverridae</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Arvicolinae</term><term>Cochons d'Inde</term><term>Cricetinae</term><term>Furets</term><term>Modèles animaux de maladie humaine</term><term>Primates</term><term>Rats</term><term>Souris</term><term>Syndrome respiratoire aigu sévère</term><term>Virus syndrome respiratoire aigu sévère</term><term>Modèle animal</term><term>Anticorps</term><term>Vaccin</term><term>Syndrome respiratoire aigu sévère</term><term>Viverridae</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) emerged in the Guangdong province of China in late 2002 and spread to 29 countries. By the end of the outbreak in July 2003, the CDC and WHO reported 8437 cases with a 9.6% case fatality rate. The disease was caused by a previously unrecognized coronavirus, SARS-CoV. Drawing on experience with animal coronavirus vaccines, several vaccine candidates have been developed and evaluated in pre-clinical trials. Available data suggest that vaccines should be based on the the 180 kDa viral spike protein, S, the only significant neutralization antigen capable of inducing protective immune responses in animals. In the absence of clinical cases of SARS, candidate vaccines should be evaluated for efficacy in animal models, and although it is uncertain whether the United States Food and Drug Administration's "animal rule" would apply to licensure of a SARS vaccine, it is important to develop standardized animal models and immunological assays in preparation for this eventuality. This report summarizes the recommendations from a WHO Technical Meeting on Animal Models and Antibody Assays for Evaluating Candidate SARS Vaccines held on 25-26 August 2005 in South Mimms, UK, provides guidance on the use of animal models, and outlines the steps to develop standard reagents and assays for immunological evaluation of candidate SARS vaccines.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></region><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Wood, John" sort="Wood, John" uniqKey="Wood J" first="John" last="Wood">John Wood</name></noRegion><name sortKey="Ferguson, Morag" sort="Ferguson, Morag" uniqKey="Ferguson M" first="Morag" last="Ferguson">Morag Ferguson</name></country><country name="Suisse"><noRegion><name sortKey="Wood, David" sort="Wood, David" uniqKey="Wood D" first="David" last="Wood">David Wood</name></noRegion><name sortKey="Cherian, Thomas" sort="Cherian, Thomas" uniqKey="Cherian T" first="Thomas" last="Cherian">Thomas Cherian</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004481 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004481 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0009303
|texte= Animal models and antibody assays for evaluating candidate SARS vaccines : Summary of a technical meeting 25-26 August 2005, London, UK
}}
| This area was generated with Dilib version V0.6.33. |  |